NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2013 Nov 29

PMID 24285980

Citations 16

Authors

Patrick J Mansky

Dawn B Wallerstedt

Timothy S Sannes

Jamie Stagl

Laura Lee Johnson

Marc R Blackman

Jean L Grem

Sandra M Swain

Brian P Monahan

Affiliations

Soon will be listed here.

Abstract

Purpose: European Mistletoe (Viscum album L.) extracts (mistletoe) are commonly used for cancer treatment in Europe. This phase I study of gemcitabine (GEM) and mistletoe in advanced solid cancers (ASC) evaluated: (1) safety, toxicity, and maximum tolerated dose (MTD), (2) absolute neutrophil count (ANC) recovery, (3) formation of mistletoe lectin antibodies (ML ab), (4) cytokine plasma concentrations, (5) clinical response, and (6) pharmacokinetics of GEM.

Methods:

Design: increasing mistletoe and fixed GEM dose in stage I and increasing doses of GEM with a fixed dose of mistletoe in stage II. Dose limiting toxicities (DLT) were grade (G) 3 nonhematologic and G4 hematologic events related to platelets and granulocytes only [corrected]; MTD was reached with 2 DLTs in one dosage level. Response in stage IV ASC was assessed with descriptive statistics. Statistical analyses examined clinical response/survival and ANC recovery.

Results: DLTs were G4 neutropenia, G4 thrombocytopenia, G4 acute renal failure, and G3 cellulitis, attributed to mistletoe. GEM 1300 mg/m(2) [corrected] and mistletoe 250 mg combined were the MTD. Of 44 patients, 24 developed nonneutropenic fever and flu-like syndrome. GEM pharmacokinetics were unaffected by mistletoe. All patients developed ML3 IgG antibodies. ANC showed a trend to increase between baseline and cycle 2 in stage I dose escalation. 6% of patients showed partial response, 42% stable disease. Median survival was 200 days. Compliance with mistletoe injections was high.

Conclusion: GEM plus mistletoe is well tolerated. No botanical/drug interactions were observed. Clinical response is similar to GEM alone.

Citing Articles

Mistletoe Extract in Patients With Advanced Pancreatic Cancer: a Double-Blind, Randomized, Placebo-Controlled Tial (MISTRAL).

Wode K, Kienle G, Bjor O, Fransson P, Sharp L, Elander N Dtsch Arztebl Int. 2024; 121(11):347-354.

PMID: 38915151 PMC: 11539882. DOI: 10.3238/arztebl.m2024.0080.

Mistletoe Extracts during the Oncological Perioperative Period: A Systematic Review and Meta-Analysis of Human Randomized Controlled Trials.

Cogo E, Elsayed M, Bhardwaj S, Cooley K, Aycho C, Liang V Curr Oncol. 2023; 30(9):8196-8219.

PMID: 37754510 PMC: 10529072. DOI: 10.3390/curroncol30090595.

Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy?.

Oei S, Schad F Cancers (Basel). 2023; 15(4).

PMID: 36831465 PMC: 9953994. DOI: 10.3390/cancers15041116.

Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance.

Chan W, Adiwidjaja J, McLachlan A, Boddy A, Harnett J Cancer Chemother Pharmacol. 2023; 91(2):103-119.

PMID: 36707434 PMC: 9905199. DOI: 10.1007/s00280-023-04504-z.

Herb-anticancer drug interactions in real life based on VigiBase, the WHO global database.

Pochet S, Lechon A, Lescrainier C, De Vriese C, Mathieu V, Hamdani J Sci Rep. 2022; 12(1):14178.

PMID: 35986023 PMC: 9391489. DOI: 10.1038/s41598-022-17704-z.

References

Kienle G, Kiene H . Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res. 2007; 12(3):103-19. View

Bussing A . Mistletoe therapy and immunological research. Anticancer Drugs. 1997; 8 Suppl 1:S65. View

Hajto T, Berki T, Palinkas L, Boldizsar F, Nemeth P . Investigation of the effect of mistletoe (Viscum album L.) extract Iscador on the proliferation and apoptosis of murine thymocytes. Arzneimittelforschung. 2006; 56(6A):441-6. DOI: 10.1055/s-0031-1296810. View

Franz H . Mistletoe lectins and their A and B chains. Oncology. 1986; 43 Suppl 1:23-34. DOI: 10.1159/000226417. View

Grossarth-Maticek R, Kiene H, Baumgartner S, Ziegler R . Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001; 7(3):57-66, 68-72, 74-6 passim. View

Hostanska K, Hajto T, Spagnoli G, Fischer J, Lentzen H, Herrmann R . A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun. 1995; 14(5-6):295-304. View

Beuth J, Ko H, Tunggal L, Steuer M, Geisel J, Jeljaszewicz J . Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo. 1993; 7(5):407-10. View

Gabius H, Andre S, Kaltner H, Siebert H, Von der Lieth C, Gabius S . [The mistletoe myth--claims, reality and provable perspectives]. Z Arztl Fortbild (Jena). 1996; 90(2):103-10. View

Gorter R, van Wely M, Reif M, Stoss M . Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern Ther Health Med. 1999; 5(6):37-44, 47-8. View

10.

Steuer-Vogt M, Bonkowsky V, Ambrosch P, Scholz M, Neiss A, Strutz J . The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer. 2001; 37(1):23-31. DOI: 10.1016/s0959-8049(00)00360-9. View

11.

Stein G, Berg P . Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Eur J Med Res. 1999; 4(5):169-77. View

12.

Lee R, Gabius H, Lee Y . Ligand binding characteristics of the major mistletoe lectin. J Biol Chem. 1992; 267(33):23722-7. View

13.

Elsasser-Beile U, Voss M, Schuhle R, Wetterauer U . Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal. 2001; 14(6):255-9. PMC: 6808059. DOI: 10.1002/1098-2825(20001212)14:6<255::aid-jcla1>3.0.co;2-j. View

14.

Bock P, Friedel W, Hanisch J, Karasmann M, Schneider B . [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results...]. Arzneimittelforschung. 2004; 54(8):456-66. DOI: 10.1055/s-0031-1296999. View

15.

Huber R, Eisenbraun J, Miletzki B, Adler M, Scheer R, Klein R . Pharmacokinetics of natural mistletoe lectins after subcutaneous injection. Eur J Clin Pharmacol. 2010; 66(9):889-97. DOI: 10.1007/s00228-010-0830-5. View

16.

Stettin A, Schultze J, Stechemesser E, Berg P . Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr. 1990; 68(18):896-900. DOI: 10.1007/BF01649034. View

17.

Ostermann T, Bussing A . Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore (NY). 2012; 8(5):277-81. DOI: 10.1016/j.explore.2012.06.005. View

18.

Ostermann T, Raak C, Bussing A . Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer. 2009; 9:451. PMC: 2804713. DOI: 10.1186/1471-2407-9-451. View

19.

RIBEREAU-GAYON G, Dumont S, Muller C, Jung M, Poindron P, Anton R . Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. Cancer Lett. 1996; 109(1-2):33-8. DOI: 10.1016/s0304-3835(96)04401-1. View

20.

Savoie A, Lavastre V, Pelletier M, Hajto T, Hostanska K, Girard D . Activation of human neutrophils by the plant lectin Viscum album agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis. J Leukoc Biol. 2000; 68(6):845-53. View